•,								Sheet I O	<u> </u>
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)				ATTY DOCKET NO. 10873-008-999		application no 09/492,764			
				APPLICANT Jove et al.					
				January 27, 2000 GROUP GROUP 1642 CO					
U.S. PATENT DOCUMENTS									
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	N	NAME	CLASS	SUBCLASS:	FILING D	ATE RIATE
KAC	CJ	5,935,993	8/10/99	Tang et al.		$\langle \zeta \rangle$	\(\frac{1}{2}\)	7.	
KAC	CK	5,972,598	10/26/99	Chaudhary et al.			(5	3/	
AL	CL	6,426,366	7/30/02	Novogrodsky et a	l.	2	2	5	
FOREIGN PATENT DOCUMENTS									
		DOCUMENT NUMBER	DATE .	co	OUNTRY	CLASS	SUBCLASS	TRANSL	
		T	1	I		Γ	<u> </u>	YES	МО
			<u> </u>			I	<u> </u>	<u> </u>	
OMETER DEPENDENCES (L. J. Jing Author Title Date Partinant Pages Fto.)									

		OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)		
	CM	Bright et al. IL-12 induced JAK-STAT pathways in T lymphocytes: Regulation by tyrphostin. J. of Allergy and		
	Clinical Immunology, 1997, 99(1 part 2):S287. Joint Meeting of the American Academy of Allergy, Asthma and			
KAC	ŀ	Immunology, the American Association of Immunologists and the Clinical Immunology Society; San Francisco, CA,		
100		USA; February 21-26, 1997		
	CN	Burger et al. IL-6 induced proliferation of a myeloma cell line is accompanied by activation of the JAK/STAT		
1	pathway and inhibited by tyrphostin AG490. Annals of Hematology, 1998, 77(suppl. 2):S2			
-	CO Han et al. Preferential inhibition of glioblastoma cells with wild-type epidermal growth factor receptors by a no			
tyrosine kinase inhibitor ethyl-2,5-dihydroxycinnamate. Oncol Res. 1997, 9(11-12):581-587				
	CP	Han et al. Tyrphostin AG 1478 preferentially inhibits human glioma cells expressing truncated rather than wild-type		
		epidermal growth factor receptors. Cancer Res. 1996, 56(17):3859-3861		
CO Heller et al. Treatment of cutaneous and subcutaneous tumors with electrochemotherapy using intralesi		Heller et al. Treatment of cutaneous and subcutaneous tumors with electrochemotherapy using intralesional		
		bleomycin. DATABASE BIOSIS (online), Biosciences information service, Philadelphia, PA, US; July 1, 1998,		
		Databse accession No. PREV199800321817. Abstract & cancer, 83(1):148-157		
	CR	Lei et al. Enhancement of chemosensitivity and programmed cell death by tyrosine kinase inhibitors correlates with		
	EGFR expression in non-small cell lung cancer cells. Anticancer Res. 1999, 19(1A):221-228			
	CS Liang et al. Chemosensitization of glioblastoma cells to bis-dichloroethyl-nitrosourea with tyrphostin AG17.			
	Cancer Res. 1998, 4(3):773-781			
	CT	Nielsen et al. Constitutive activation of a slowly migrating isoform of Stat3 in mycosis fungoides: tyrphostin AG490		
		inhibits Stat3 activation and growth of mycosis fungoides tumor cell lines. Proc. Natl. Acad. Sci. U.S.A. 1997,		
		94(13):6764-6769		
	CU	Palumbo et al. The tryphostin AG17 induces apoptosis and inhibition of cdk2 activity in a lymphoma cell line that		
overexpresses bcl-2. Cancer Res. 1997, 57(12):2434-2439		·		
	CV	Penar et al. Inhibition of epidermal growth factor receptor-associated tyrosine kinase blocks glioblastoma invasion of		
A		the brain. Neurosurgery. 1997, 40(1):141-151		

BY HAND DELIVERY

:	· <u>·</u>		Sheet 1012
	pai	CW	Tsai et al. Enhancement of chemosensitivity by tyrphostin AG825 in high-p185(neu) expressing non-small cell lung cancer cells. Cancer Res. 1996, 56(5):1068-1074
İ		CX	Zushi et al. STAT3 mediates the survival signal in oncogenic ras-transfected intestinal epithelial cells. Int J Cancer. 1998, 78(3):326-330
		CY	Zushi et al. Role of heparin-binding EGF-related peptides in proliferation and apoptosis of activated ras-stimulated intestinal epithelial cells. Int. J. Cancer 1997, 73(6):917-923
	V		

EXAMINER Jaren J. Camelle	DATE CONSIDERED	est 05/27/04					
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							